Niraparib (Zejula) 100 mg capsules changing to tablets

What is happening?

Following Medsafe approval, GlaxoSmithKline (the supplier) advised that Zejula capsules are changing to tablets. Medsafe has reviewed the new formulation and found that the tablets meet New Zealand standards of safety, quality and efficacy.

There are two pack sizes, an 84-pack and a 56-pack. The 84-pack completed its move to tablets in 2025. 

56-pack details

• Chemical: Niraparib
• Presentation: Cap 100 mg
• Brand: Zejula
• Pharmacode: 2635232 
• Subsidy: $8929.84
• Wastage claimable 

Schedule listing for Zejula(external link)

People taking Zejula should not notice a difference

The tablets have the same active ingredient in the same dose. They will work in your body the same way. You should continue to take the tablets the same way as the capsules.

When is this happening?

1 November 2024 | 84-pack of tablets listed on the Schedule. 

1 July 2025 | delisting of 84-pack of capsules

1 January 2026 | 56-pack of tablets listed (Pharmacode: 2690691)

1 October 2026 | delisting of 56-pack of capsules (Pharmacode: 2635232)

Who to contact

People who take niraparib should talk to a health care professional they trust, such as their doctor or pharmacist., if they have questions about this change. Pharmac cannot comment on anyone's individual clinical circumstances.

If you have questions about the funding or supply of this medicine, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)